You are here

  • Home
  • Online First
  • Prevotella copri in individuals at risk for rheumatoid arthritis

Article Text

Article menu

other Versions

Download PDFPDF
Rheumatoid arthritis
Prevotella copri in individuals at risk for rheumatoid arthritis
  1. Deshire Alpizar-Rodriguez1,
  2. Till Robin Lesker2,
  3. Achim Gronow2,
  4. Benoît Gilbert1,
  5. Elena Raemy1,
  6. Celine Lamacchia1,
  7. Cem Gabay1,
  8. Axel Finckh1,
  9. Till Strowig2,3
  1. 1Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland
  2. 2Department of Microbial Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany
  3. 3Hannover Medical School, Hannover, Germany
  1. Correspondence to Dr Axel Finckh, Division of Rheumatology, Geneva University Hospital, Geneva 1205, Switzerland; axel.finckh{at}hcuge.ch; Dr Till Strowig, Department of Microbial Immune Regulation, Helmholtz Centre for Infection Rsearch, Braunschweig 38124, Germany; Till.Strowig{at}helmholtz-hzi.de

Abstract

Objectives Rheumatoid arthritis (RA) has been associated with a relative expansion of faecal Prevotellaceae. To determine the microbiome composition and prevalence of Prevotella spp. in a group of individuals at increased risk for RA, but prior to the development of the disease.

Methods In an ongoing cohort study of first-degree relatives (FDRs) of patients with RA, we identified ‘FDR controls’, asymptomatic and without autoantibodies, and individuals in pre-clinical RA stages, who had either developed anticitrullinated peptide antibodies or rheumatoid factor positivity and/or symptoms and signs associated with possible RA. Stool sampling and culture-independent microbiota analyses were performed followed by descriptive statistics and statistical analyses of community structures.

Results A total of 133 participants were included, of which 50 were categorised as ‘FDR controls’ and 83 in ‘pre-clinical RA stages’. The microbiota of individuals in ‘pre-clinical RA stages’ was significantly altered compared with FDR controls. We found a significant enrichment of the bacterial family Prevotellaceae, particularly Prevotella spp., in the ‘pre-clinical RA’ group (p=0.04).

Conclusions Prevotella spp. enrichment in individuals in pre-clinical stages of RA, before the onset of RA, suggests a role of intestinal dysbiosis in the development of RA.

  • microbiome
  • rheumatoid arthritis
  • epidemiology of ra
  • pre-clinical stages of ra

https://doi.org/10.1136/annrheumdis-2018-214514

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • DA-R and TRL are joint first authors.

    • AF and TS contributed equally.

    • Handling editor Josef S Smolen

    • Correction notice This article has been corrected sinceit published Online First. The equal contributor statement has been added and the correspondence details updated.

    • Contributors DAR, TRL, AF and TS designed the study. DAR, ER, CL and AF were involved in patient recruitment, samples and data collecting. TRL, AG and TS were involved in samples processing and analysis. DAR, AF, TS and TRL were involved in statistical analyses and interpretation of data. All authors were involved in writing the manuscript and approved the final version. The first authors and corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

    • Funding DAR granted the Abbvie Grant 2016 and the Swiss Government Excellence Scholarship for PhD studies of The Federal Commission for Scholarships for Foreign Students. The work was supported by grants from the EU (StG337251) and Helmholtz Association (VH-NG-933) to TS. No other specific funding was received to carry out the work described in this article.

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Ethics approval The protocol was approved by the ethics committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement Raw data are available upon request from the corresponding author.